FDA recall of transvaginal mesh applies to some, but not all, pelvic floor procedures, urogynecologist Dr. Marie Fidela Paraiso explains.
Study is the first of its kind to compare an intraperitoneal versus an extraperitoneal approach to prolapse surgery on a large scale.
New elastogenic therapies based on nanotechnology could one day help women with pelvic organ prolapse.
Pelvic organ prolapse treatment options for elderly women should not be based on chronological age alone. Patients’ symptom concerns, functional status, attitudes and preferences are all key factors in the treatment decision.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic’s new risk calculator is more accurate than presurgical stress testing and expert predictions for de novo incontinence after pelvic organ prolapse surgery.
Cleveland Clinic researchers have for the first time described the natural evolution of pelvic organ prolapse (POP) in patients seeking treatment. Almost half of women with symptomatic POP will have prolapse progression within a year. When the leading edge of prolapse is beyond the hymen, the chance of progression is doubled.
Cleveland Clinic researchers have found that intraperitoneally injected mesenchymal stem cells home to pelvic organs in an animal model of pelvic organ prolapse (POP) after simulated childbirth delivery, confirming that tissue injury plays a role in the homing of these cells. The results could be relevant for future stem cell-based therapies for delivery-related disorders such as POP.